Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose

NCT02544685 is registered in ClinicalTrials.gov with S&D Pharma SK s.r.o. as lead sponsor.

NCT NCT02544685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02544685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose
Lead sponsor
S&D Pharma SK s.r.o.
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2010
Completion date
October 31, 2019
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, febrile neutropenia, infection in an immunocompromised host, neutropenia